Literature DB >> 28527051

New treatments for headache.

Kasra Maasumi1, Stewart J Tepper2, Alan M Rapoport3.   

Abstract

Headache disorders are common worldwide and often disabling. Until recently, treatments were borrowed from other branches of neurology and medicine. Monoclonal antibodies targeting calcitonin gene-related peptide (CGRP) ligand and receptor, small molecule CGRP receptor antagonist gepants, serotonin1F agonists, new devices to deliver currently available drugs, and neuromodulation devices have recently been in the forefront of headache treatments that are rather specific for various headache disorders. These novel therapies are changing the field of headache medicine. Herein, we update the latest data available for these therapies.

Entities:  

Keywords:  Calcitonin gene-related peptide (CGRP); Headache treatment; Magnetic stimulation; Monoclonal antibodies; Neuromodulation; Neurostimulation

Mesh：

Substances：

Year:  2017        PMID： 28527051     DOI： 10.1007/s10072-017-2910-0

Source DB:  PubMed          Journal:  Neurol Sci        ISSN： 1590-1874            Impact factor:   3.307


  85 in total

1.  BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study.

Authors:  Hans-Christoph Diener; Piero Barbanti; Carl Dahlöf; Uwe Reuter; Julia Habeck; Jana Podhorna
Journal:  Cephalalgia       Date:  2010-12-20       Impact factor: 6.292

Review 2.  CGRP and its receptors provide new insights into migraine pathophysiology.

Authors:  Tony W Ho; Lars Edvinsson; Peter J Goadsby
Journal:  Nat Rev Neurol       Date:  2010-09-07       Impact factor: 42.937

3.  High-rate repetitive transcranial magnetic stimulation in migraine prophylaxis: a randomized, placebo-controlled study.

Authors:  Usha K Misra; Jayantee Kalita; Sanjeev K Bhoi
Journal:  J Neurol       Date:  2013-08-21       Impact factor: 4.849

4.  Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine.

Authors:  T W Ho; L K Mannix; X Fan; C Assaid; C Furtek; C J Jones; C R Lines; A M Rapoport
Journal:  Neurology       Date:  2007-10-03       Impact factor: 9.910

5.  Stimulation of the posterior hypothalamus for treatment of chronic intractable cluster headaches: first reported series.

Authors:  Angelo Franzini; Paolo Ferroli; Massimo Leone; Giovanni Broggi
Journal:  Neurosurgery       Date:  2003-05       Impact factor: 4.654

6.  Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine.

Authors:  Jes Olesen; Hans-Christoph Diener; Ingo W Husstedt; Peter J Goadsby; David Hall; Ulrich Meier; Stephane Pollentier; Lynna M Lesko
Journal:  N Engl J Med       Date:  2004-03-11       Impact factor: 91.245

7.  Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial.

Authors:  Tony W Ho; Michel D Ferrari; David W Dodick; Vince Galet; James Kost; Xiaoyin Fan; Heather Leibensperger; Samar Froman; Christopher Assaid; Christopher Lines; Hille Koppen; Paul K Winner
Journal:  Lancet       Date:  2008-11-25       Impact factor: 79.321

8.  Acute treatment of intractable migraine with sphenopalatine ganglion electrical stimulation.

Authors:  Stewart J Tepper; Ali Rezai; Samer Narouze; Charles Steiner; Pouya Mohajer; Mehdi Ansarinia
Journal:  Headache       Date:  2009-05-26       Impact factor: 5.887

9.  Hypothalamic deep brain stimulation for cluster headache: experience from a new multicase series.

Authors:  T Bartsch; M O Pinsker; D Rasche; T Kinfe; F Hertel; H C Diener; V Tronnier; H M Mehdorn; J Volkmann; G Deuschl; J K Krauss
Journal:  Cephalalgia       Date:  2008-03       Impact factor: 6.292

10.  Safety and patients' satisfaction of transcutaneous supraorbital neurostimulation (tSNS) with the Cefaly® device in headache treatment: a survey of 2,313 headache sufferers in the general population.

Authors:  Delphine Magis; Simona Sava; Tullia Sasso d'Elia; Roberta Baschi; Jean Schoenen
Journal:  J Headache Pain       Date:  2013-12-01       Impact factor: 7.277
View more
  3 in total

1.  Interictal levels of calcitonin gene related peptide in gingival crevicular fluid of chronic migraine patients.

Authors:  Reza Fekrazad; Ahmadreza Sardarian; Kamran Azma; Masoumeh Karami; Afshin Borhani-Haghighi; Behrouz Gharesi-Fard; Bahram Movahedi
Journal:  Neurol Sci       Date:  2018-04-13       Impact factor: 3.307

Review 2.  A new era in headache treatment.

Authors:  Michail Vikelis; Konstantinos C Spingos; Alan M Rapoport
Journal:  Neurol Sci       Date:  2018-06       Impact factor: 3.307

Review 3.  Non-pharmacological Approaches for Headaches in Young Age: An Updated Review.

Authors:  Frank Andrasik; Licia Grazzi; Emanuela Sansone; Domenico D'Amico; Alberto Raggi; Eleonora Grignani
Journal:  Front Neurol       Date:  2018-11-27       Impact factor: 4.003
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.